Nadroparin Calcium

那曲肝素钙

Report date: 2023/01/13 20:00:32
NME

Base Information

Drug NameNadroparin Calcium
Drug Alias Name那屈肝素钙nadroparine calciquenadroparinum calcicumFraxiparinSeleparina +[9] 
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionPlatelet aggregation inhibitors
TargetsNot applicable
Therapy Area/IndicationsVenous ThrombosisNeoplasm MetastasisNeoplasms
Global Approved IndicationsVenous Thrombosis
Approved Indications in ChinaVenous Thrombosis
Original Approved Country/TerritoryMainland China
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[14] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesSanofi-SynthelaboZhaoke Pharmaceutical (Hefei) Co LtdAspen Pharmacare Holdings Ltd
Inactive CompaniesCanadian Institutes Of Health Research (Cihr)ItalfarmacoGlaxosmithkline Plc +[4] 
Active IndicationsVenous Thrombosis
Inactive IndicationsNeoplasm MetastasisNeoplasms

Other Information

ATC CodeB01AB06
Related LinksWikipediaDrugBankKEGG